Caspofungin for invasive aspergillosis: A single-centre prospective study.

Sub-category: Supportive Care
Category: Patient and Survivor Care
Meeting: 2009 ASCO Annual Meeting
Session Type and Session Title: This abstract will not be presented at the 2009 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No: e20618

Citation: J Clin Oncol 27, 2009 (suppl; abstr e20618)

Author(s): A. Bonini, A. Tieghi, B. Gamberi, A. Imovilli, C. Carbonelli, L. Spaggiari, L. Gugliotta; Azienda Ospedaliera ASMN, Reggio Emilia, Italy

Abstract:

Background: Infections are the main complication for neutropenic patients (pts). Fungal infections represent a frequent cause of death. Caspofungin (Caspo) is the first drug able to inhibit the growth of the fungal cell wall. Methods: Since 2004 we began a prospective study with the administration of Caspo as first line therapy in 63 consecutive adult neutropenic pts. With persistent fever despite antibiotics, a chest CT-scan and galactomannan test were performed. In case of probable or proven infection Caspo was administered at the dose of 70 mg on the first day followed by 50 mg daily. They were 35 males and 28 females; the mean age was 56 yrs. The diagnoses were: leukemia 44, myeloma 3, lymphoma 16; the disease's phases were: new onset 24, remission 16, relapse 23. 12 pts received an allogeneic and 6 an autologous transplant; the others received conventional chemotherapy. Results: Fungal infections were proven in 12 and probable in 51 cases. The first site of infection was the lung in 62 pts. CT scan was positive (halo sign or air-crescent sign) in all the pts with a lung localization. BAL was performed in 37 pts. The mean time of treatment was 18 days. Caspo was well tolerated and not discontinued for adverse events. Among pts submitted to an allogeneic HSCT the concomitant therapy with Cyclosporin A was not influenced by Caspo. No adverse events during the infusion were seen, and it was not necessary to administer any premedication. The global (partial and complete) response was 50/63 (79%); 13 pts died for fungal infection. The responses were generally similar for probable and proven infections. No breakthrough infections were seen. All surviving patients, upon discharge from the hospital, received oral treatment with voriconazole. For all the cured pts, there was a concomitant recovery of neutrophils and this seems crucial for the resolution of the infection. Conclusions: The resolution rate of the infections is very high; Caspo seems safe, it does not preclude any other treatment, it is well tolerated and the cost is lower than other antifungal treatments.